Avelumab
Avelumab is a programmed death receptor-1 (PD-1)–blocking antibody or immune checkpoint inhibitor.
The drug has several FDA-approved indications, including adults and pediatric patients 12 years and older with:
- Metastatic Merkel cell carcinoma
- Renal cell carcinoma
- Certain patients with urothelial carcinoma
Provider Resource
